Production of Bispecific Antibodies
- 1 June 1995
- journal article
- review article
- Published by Wiley in Current Protocols in Immunology
- Vol. 14 (1), 2.13.1-2.13.16
- https://doi.org/10.1002/0471142735.im0213s14
Abstract
Bispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this unit. Protocols are also presented for producing BsAbs by fusing two antibody‐producing hybridomas that can be selected for based on drug resistance, or by double labeling with fluorochromes and FACS. Support protocols describe screening and purification of bsAbs.Keywords
This publication has 15 references indexed in Scilit:
- Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19)Clinical and Experimental Immunology, 1992
- Bispecific IgA/IgM antibodies and their use in enzyme immunoassayJournal of Immunological Methods, 1992
- High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody FragmentNature Biotechnology, 1992
- Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.The Journal of Experimental Medicine, 1992
- Production of hybrid hybridomas based on HATs-neomycinr double mutantsJournal of Immunological Methods, 1989
- Enrichment and Selection of Hybrid Hybridomas by Percoll Density Gradient Centrifugation and Fluorescent-Activated Cell SortingHybridoma, 1988
- Purification of monoclonal antibodies from ascites using ABx liquid chromatography columnJournal of Immunological Methods, 1987
- Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorterJournal of Immunological Methods, 1987
- Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.The Journal of Experimental Medicine, 1984
- Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagentBiochemical Journal, 1978